



RAPID HIV-1/2

antibody test

Features:

- Fastest HIV-1/-2 rapid test with instant results
- Easy-to-use with simple interpretation
- FDA approved and CDC validated results
- Room-temperature storage
- No timers or specialized equipment needed
- Built-in procedural and reagent control line External test controls available as an accessory*

The only thing more important than knowing—is knowing faster.

Reveal® G4 HIV-1/-2 is the next generation of rapid testing for HIV using MedMira's patented Rapid Vertical Flow (RVF) Technology™. Able to provide instant results (5 times faster than any lateral "ow test) in three steps available in Point-of-Care (POC) and Laboratory formats. Reveal® G4 HIV-1/-2 can be used for serum, plasma, whole blood or ÿngerstick whole blood.

Reveal® G4 HIV-1/-2 allows healthcare professionals the fastest easy-to-use HIV rapid test with the highest quality. MedMira's tests have a unique in-built procedural and reagent control line, to give a 100% security that the test is functioning and the procedural steps were completed correctly.



Thomas

Technology and Performance

Testing whole blood specimens with Reveal® G4 provides a higher degree of accuracy than some traditional, more time-consuming laboratory tests:

	Sensitivity	Specificity
HIV-1	99.80%	99.90%
HIV-2	100%	100%*

Technology

Reveal® G4 is the latest application of MedMira's patented Rapid Vertical Flow (RVF) Technology for U.S. customers—allowing for the testing of ÿngerstick, whole blood specimens in addition to serum and plasma. This product builds upon the performance of MedMira's Reveal product line, which enjoyed excellent clinical performance in rigorous evaluations and inspections and consistently ranks as a leading choice in rapid HIV tests for U.S. hospitals. Additionally, research demonstrates that MedMira's rapid HIV test detects early infection better than other rapid tests and closely matches the performance of much more complicated enzyme immunoassay tests.

^{*}Reveal® G4 HIV-1/2 test controls are designed for use in customer quality assurance practices, stored at room temperature until ready for use. Each vial is su cient to perform ÿve Reveal® G4 HIV-1/2 tests.





RAPID HIV-1/2

antibody test

Ordering Information and MedMira Cat. No.

POC for fingerstick whole blood **Thomas No. CHM06Z604** Cat. No. 815311007583 Qty. 20 tests

HIV-1 Antibody Test Controls **Thomas No. CHM06Z605** Cat. No. 815311007590 Qty. 1 positive/ 1 negative

For more information on Reveal G4, please contact your Thomas Scientific Representative.

Test. Results. Treatment. And the patient never left.

Reveal® G4 HIV-1/-2 is the next generation of rapid testing for HIV using MedMira's patented Rapid Vertical Flow (RVF) Technology™. Able to provide instant results (5 times faster than any lateral ~ow test) in three steps using ÿngerstick whole blood, Reveal® G4 HIV-1/-2 allows healthcare professionals at Point-of-Care (POC) settings to test easily for HIV, deliver clear results, and begin treatment immediately if needed.

MedMira's POC rapid tests provide everything needed such as lancet, alcohol swab etc. The easy-to-use application combined with its less than 3 minutes procedure (from opening the package to the end result) with instant results, allow an immediate answer.





Reveal® G4 HIV-1/2 is the solution for fast, easy and reliable HIV testing:

- Public Health Programs
- Voluntary Testing & Counseling Centers
- Pharmacies & Physicians' O_cces
- Immigration Screening
- Workplace Wellness Programs
- Military Medical Units
- Convenience Care Clinics
- Correctional Facilities
- Displaced Populations Camps
- Emergency Department & First Responders
- Mobile Clinics

According to the CDC, more than 55% of patients tested are discharged before receiving their HIV test results. For patients, the anxiety of awaiting results is eliminated with real-time results, encouraging regular testing, more awareness of HIV status, and better patient outcomes. Potential patient counseling and treatment can begin immediately. Post-exposure treatment, if begun quickly, can reduce the risk of HIV transmission, and fewer patients slip through the cracks due to the need for follow-up with a potentially at-risk population.

















Efficiency and Quality - tailor made for Health Care Professionals

Reveal® G4 HIV-1/-2 is also available in two laboratory formats (whole blood or serum/plasma) which allows for the highest e ciency and allows for batch testing. Both formats have been speciÿcally designed for laboratories or any setting which has a high demand on screening. These formats allow for less than 2 minutes procedure with instant results.

- Reveal® G4 HIV-1/-2 **LAB+** Format: is for whole blood (venipuncture), serum or plasma.
- Reveal® G4 HIV-1/-2 LAB S/P Format: is for serum and plasma only.

One of the unique advantages of MedMira's patented Rapid Vertical Flow (RVF) Technology™ is that results do not disappear and hence provide long lasting proof of results. Reveal® G4 HIV-1/2 helps healthcare professionals prevent and contain the spread of HIV in any setting.



Patient Health and Employee Safety

With capabilities to test whole blood samples in addition to plasma and serum samples, healthcare workers in a variety of roles can determine appropriate next steps in treatment from Reveal® G4's easy-to-read results. Reveal® G4's instantaneous results on the HIV status of the specimen in question allow for immediate treatment to begin in the case of a reactive result.

In addition to helping patients know their own status, Reveal® G4 is also an integral tool in occupational safety where more than 8 million healthcare workers face the risk of becoming infected with HIV through accidental exposure to blood. In the United States, approximately one million accidental needlesticks occur each year. In such cases, the status of the source patient must be determined as quickly as possible so that decisions about pursuing post-exposure prophylaxis (PEP) can be made

Reveal® G4 makes the di erence in lab and healthcare settings by providing instant results, reducing the chances of HIV transmission, and decreasing the period of anxiety while waiting for results. This also potentially saves the cost of expensive retroviral therapy before the source specimen's status is determined.



















